Shining More Light on RAS Inhibition during the COVID-19 Pandemic.
作者信息
Rianto Fitra, Sparks Matthew A
机构信息
Division of Nephrology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina.
Renal Section, Durham Veterans Affairs Health Care System, Durham, North Carolina.
出版信息
Clin J Am Soc Nephrol. 2021 Jul;16(7):1002-1004. doi: 10.2215/CJN.06000521. Epub 2021 Jul 12.
Abstract
摘要
相似文献
1
Shining More Light on RAS Inhibition during the COVID-19 Pandemic.在新冠疫情期间，进一步揭示RAS抑制作用
Clin J Am Soc Nephrol. 2021 Jul;16(7):1002-1004. doi: 10.2215/CJN.06000521. Epub 2021 Jul 12.
2
Angiotensin-converting enzyme 2 as a versatile player in the management of coronavirus disease 2019.血管紧张素转换酶2在2019冠状病毒病管理中的多面角色
J Diabetes Investig. 2020 Sep;11(5):1120-1122. doi: 10.1111/jdi.13346. Epub 2020 Aug 25.
3
[Continuation of ACEI/ARB treatment in patients diagnosed with COVID-19].确诊新冠肺炎患者继续使用血管紧张素转换酶抑制剂/血管紧张素Ⅱ受体阻滞剂治疗
Aten Primaria. 2021 Jun-Jul;53(6):102068. doi: 10.1016/j.aprim.2021.102068. Epub 2021 Mar 30.
4
COVID-19, hypertension, and RAAS blockers: the BRACE-CORONA trial.2019冠状病毒病、高血压与肾素-血管紧张素-醛固酮系统阻滞剂：BRACE-CORONA试验
Cardiovasc Res. 2020 Dec 1;116(14):e198-e199. doi: 10.1093/cvr/cvaa325.
5
Antihypertensive Drugs and COVID-19 Risk: A Cohort Study of 2 Million Hypertensive Patients.抗高血压药物与 COVID-19 风险：一项涉及 200 万高血压患者的队列研究。
Hypertension. 2021 Mar 3;77(3):833-842. doi: 10.1161/HYPERTENSIONAHA.120.16314. Epub 2021 Jan 11.
6
Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19.冠状病毒与 ACE2、血管紧张素 II 和 RAS 抑制剂的相互作用——来自现有证据的教训和对 COVID-19 的深入了解。
Hypertens Res. 2020 Jul;43(7):648-654. doi: 10.1038/s41440-020-0455-8. Epub 2020 Apr 27.
7
Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update.血管紧张素转换酶 2 和肾素血管紧张素系统抑制剂在 COVID-19 中的应用：最新进展。
High Blood Press Cardiovasc Prev. 2021 Mar;28(2):129-139. doi: 10.1007/s40292-021-00439-9. Epub 2021 Feb 26.
8
COVID-19 and Comorbid Hypertension: Is ACE2 the Culprit?新型冠状病毒肺炎与高血压合并症：血管紧张素转换酶2是罪魁祸首吗？
Prehosp Disaster Med. 2020 Dec;35(6):700-701. doi: 10.1017/S1049023X20001090. Epub 2020 Aug 25.
9
Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19.假说：血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂可能会增加 COVID-19 重症风险。
J Travel Med. 2020 May 18;27(3). doi: 10.1093/jtm/taaa041.
10
Do ACE inhibitors and angiotensin receptor antagonists increase the risk of severe COVID-19?血管紧张素转换酶抑制剂和血管紧张素受体拮抗剂会增加患重症新型冠状病毒肺炎的风险吗？
Tidsskr Nor Laegeforen. 2020 May 14;140(9). doi: 10.4045/tidsskr.20.0411. Print 2020 Jun 16.
本文引用的文献
1
Renin-Angiotensin System Blockers and the Risk of COVID-19-Related Mortality in Patients with Kidney Failure.肾素-血管紧张素系统阻滞剂与肾衰竭患者 COVID-19 相关死亡率的关系。
Clin J Am Soc Nephrol. 2021 Jul;16(7):1061-1072. doi: 10.2215/CJN.18961220. Epub 2021 Jun 4.
2
Renin-angiotensin system blockade in the COVID-19 pandemic.新型冠状病毒肺炎大流行中的肾素-血管紧张素系统阻断
Clin Kidney J. 2021 Feb 2;14(Suppl 1):i48-i59. doi: 10.1093/ckj/sfab026. eCollection 2021 Mar.
3
Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis.血管紧张素-肾素-醛固酮系统抑制剂与 COVID-19 患者临床结局的相关性：系统评价和荟萃分析。
JAMA Netw Open. 2021 Mar 1;4(3):e213594. doi: 10.1001/jamanetworkopen.2021.3594.
4
Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial.COVID-19 患者入院后停用与继续使用血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂对存活日数和出院日数的影响：一项随机临床试验。
JAMA. 2021 Jan 19;325(3):254-264. doi: 10.1001/jama.2020.25864.
5
Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial.COVID-19 患者住院期间继续或停用肾素-血管紧张素系统抑制剂：一项前瞻性、随机、开放标签试验。
Lancet Respir Med. 2021 Mar;9(3):275-284. doi: 10.1016/S2213-2600(20)30558-0. Epub 2021 Jan 7.
6
Outcomes of patients with end-stage kidney disease hospitalized with COVID-19.伴有 COVID-19 的终末期肾病患者的住院结果。
Kidney Int. 2020 Dec;98(6):1530-1539. doi: 10.1016/j.kint.2020.07.030. Epub 2020 Aug 15.
7
COVID-19 and kidney transplantation: Results from the TANGO International Transplant Consortium.COVID-19 与肾移植：TANGO 国际移植联合会的研究结果。
Am J Transplant. 2020 Nov;20(11):3140-3148. doi: 10.1111/ajt.16185. Epub 2020 Aug 4.
8
Sound Science before Quick Judgement Regarding RAS Blockade in COVID-19.在对COVID-19中的RAS阻断进行快速判断之前的可靠科学依据。
Clin J Am Soc Nephrol. 2020 May 7;15(5):714-716. doi: 10.2215/CJN.03530320. Epub 2020 Mar 27.
9
Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?高血压和糖尿病患者感染新型冠状病毒肺炎（COVID-19）的风险会增加吗？
Lancet Respir Med. 2020 Apr;8(4):e21. doi: 10.1016/S2213-2600(20)30116-8. Epub 2020 Mar 11.
10
Preventing a covid-19 pandemic.预防新冠疫情。
BMJ. 2020 Feb 28;368:m810. doi: 10.1136/bmj.m810.
Zotero 插件